Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-T and TMLI in Acute Leukemias and MDS
NCT06195891Phase 1Suspended
- Sponsor
- City of Hope
- Start
- May 2024
- Primary completion
- Mar 2030
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regulatory T-cell enriched infusion in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoint: Incidence of adverse events. Started May 2024; status: suspended.
02
Drugs
regulatory T-cell enriched infusion
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06195891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195891.